|
| 注射用哌拉西林/舒巴坦治疗泌尿系统感染的疗效评价 |
| The Central Hospital of Yiyang City, Yiyang 413000, Hunan,China |
| |
| DOI： |
| 中文关键词: 哌拉西林/舒巴坦 美洛西林/舒巴坦 泌尿系统感染 疗效评价 |
| 英文关键词:Piperacillin/sulbactam Mezlocillin/sulbactam Urinary system tract infection Evaluation of the clinical effectiveness |
| 基金项目: |
|
| 摘要点击次数: 1181 |
| 全文下载次数: 1244 |
| 中文摘要: |
| 摘 要 目的：比较哌拉西林/舒巴坦与美洛西林/舒巴坦治疗急性细菌性中重度泌尿系统感染的临床疗效，评价其有效性和安全性。方法：76例急性细菌性中重度泌尿系统感染患者随机分为试验组和对照组各38例, 分别给予哌拉西林/舒巴坦2.5 g或美洛西林/舒巴坦.5 g，溶于0.9%氯化钠注射液250 ml，ivd，q8h或q12h，1个疗程为7 d。连续治疗2个疗程后对两组临床疗效、细菌学疗效、药品不良反应等进行综合评价。结果：试验组和对照组痊愈率分别为57.9%和47.4%，总有效率分别为84.2%和78.9%。两组细菌清除率分别为89.2%和82.5%，治疗后细菌转阴率分别为89.5%和86.9%；不良反应发生率均为2.63%。两组各项评价指标比较，差异均无统计学意义（P>0.05）。结论：哌拉西林/舒巴坦对于治疗急性细菌性中重度泌尿系统感染安全有效。 |
| 英文摘要: |
| ABSTRACT Objective:To evaluate of the clinical effect and safety of PIP/SBT and MEZ/SBT in the treatment of moderate and severe acute bacterial infection of the urinary system tract.Methods:76 urinary tract infection patients were randomly divided into trial drug group(PIP/SBT) and controlled drug group(MEZ/SBT) with 38 cases each, 7 days for a course of treatment. After 2 courses of treatment, their clinical bacteriological efficacy and adverse events were evaluated. Results:The cure rates of the trial drug group and controlled drug group were 57.9% and47.4%, and the total effective rates were 84.2%and 78.9%. Their bacterial clearance rates were 89.2% and 82.5%, the negative rates of bacteria after treatment were 89.5% and 86.9%, and the adverse effects rate of the two groups was 2.63%. There was no significant difference in each evaluation index（P>0.05）. Conclusion:PIP/SBT had their good clinical effect and safety in the treatment of the moderate and severe acute bacterial urinary system tract infection. |
| 查看全文 查看/发表评论 下载PDF阅读器 |
| 关闭 |
